Doxorubicin Paradoxically Ameliorates Tumor-Induced Inflammation in Young Mice
Doxorubicin (DOX) is one of the most widely used chemo-therapeutic agents in pediatric oncology. DOX elicits an inflammatory response in multiple organs, which contributes to DOX-induced adverse effects. Cancer itself causes inflammation leading to multiple pathologic conditions. The current study i...
Main Authors: | Ibrahim Y. Abdelgawad, Marianne K. O. Grant, Flavia E. Popescu, David A. Largaespada, Beshay N. Zordoky |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/16/9023 |
Similar Items
-
Metformin mitigates SASP secretion and LPS-triggered hyper-inflammation in Doxorubicin-induced senescent endothelial cells
by: Ibrahim Y. Abdelgawad, et al.
Published: (2023-04-01) -
Exposure to Doxorubicin Modulates the Cardiac Response to Isoproterenol in Male and Female Mice
by: Kevin Agostinucci, et al.
Published: (2023-03-01) -
Juvenile exposure to doxorubicin alters the cardiovascular response to adult-onset psychosocial stress in mice
by: Marianne K. O. Grant, et al.
Published: (2022-01-01) -
EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
by: Ibrahim Y. Abdelgawad, et al.
Published: (2022-06-01) -
Doxorubicin and Doxorubicin-loaded Nanoliposome Triggers Hepatocyte Cells Senescence through Accumulation of Inflammatory Factors and Activation of P53
by: Nazanin Rahmanian, et al.
Published: (2022-02-01)